Here's What Key Metrics Tell Us About Collegium Pharmaceutical (COLL) Q3 Earnings

Collegium Pharmaceutical (COLL) reported $209.36 million in revenue for the quarter ended September 2025, representing a year-over-year increase of 31.4%. EPS of $2.25 for the same period compares to $1.61 a year ago.The reported revenue represents a surprise of +10.35% over the Zacks Consensus Estimate of $189.73 million. With the consensus EPS estimate being $1.88, the EPS surprise was +19.68%.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.Here is how Collegium Pharmaceutical performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:Total product revenues- Belbuca: $58.26 million versus the three-analyst average estimate of $53.64 million. The reported number represents a year-over-year change of +9.5%.Total product revenues- Xtampza ER: $50.48 million versus the three-analyst average estimate of $51.23 million. The reported number represents a year-over-year change of +2%.Total product revenues- Jornay PM: $41.8 million versus $37.33 million estimated by three analysts on average.Total product revenues- Nucynta: $54.8 million versus the three-analyst average estimate of $44.19 million. The reported number represents a year-over-year change of +21.4%.Total product revenues- Symproic: $4.03 million versus the three-analyst average estimate of $3.33 million. The reported number represents a year-over-year change of +12.7%.View all Key Company Metrics for Collegium Pharmaceutical here>>>Shares of Collegium Pharmaceutical have returned +8.2% over the past month versus the Zacks S&P 500 composite's +1.3% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.Zacks' Research Chief Names "Stock Most Likely to Double"Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.This top pick is a little-known satellite-based communications firm. Space is projected to become a trillion dollar industry, and this company's customer base is growing fast. Analysts have forecasted a major revenue breakout in 2025. Of course, all our elite picks aren't winners but this one could far surpass earlier Zacks' Stocks Set to Double like Hims & Hers Health, which shot up +209%.Free: See Our Top Stock And 4 Runners UpWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Collegium Pharmaceutical, Inc. (COLL): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks